647 related articles for article (PubMed ID: 16102657)
1. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
2. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
3. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy with heart.
Randell P; Moyle G
Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
[TBL] [Abstract][Full Text] [Related]
5. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
[TBL] [Abstract][Full Text] [Related]
6. Metabolic complications of HIV therapy.
Chow DC; Day LJ; Souza SA; Shikuma CM
IAPAC Mon; 2006 Sep; 12(9):302-17. PubMed ID: 17378067
[No Abstract] [Full Text] [Related]
7. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
Barbaro G
Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
[TBL] [Abstract][Full Text] [Related]
8. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
9. [Disorders of lipid and glucose metabolism. Long-term adverse effects of antiretroviral therapy].
Landauer N; Goebel FD
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():16-8. PubMed ID: 12043065
[TBL] [Abstract][Full Text] [Related]
10. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
Bevilacqua M; Dominguez LJ; Barbagallo M
J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
[TBL] [Abstract][Full Text] [Related]
11. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
Leclercq P; Blanc M
Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?
Cossarizza A; Mussini C; Viganò A
Bioessays; 2001 Nov; 23(11):1070-80. PubMed ID: 11746223
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
15. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
Holstein A; Plaschke A; Egberts EH
Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
[TBL] [Abstract][Full Text] [Related]
16. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
Crook M
Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292
[TBL] [Abstract][Full Text] [Related]
17. Current clinical issues impacting the lives of patients living with HIV/AIDS.
Gallagher DM
J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S11-6. PubMed ID: 17275717
[TBL] [Abstract][Full Text] [Related]
18. The metabolic puzzle during the evolution of HIV infection.
Salas-Salvadó J; García-Lorda P
Clin Nutr; 2001 Oct; 20(5):379-91. PubMed ID: 11534932
[TBL] [Abstract][Full Text] [Related]
19. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
20. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
Samaras K
J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
